Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
South Korea's Aprogen, which has teamed up with Japan's Nichi-Iko, is set to receive an official regulatory approval for its biosimilar infliximab in Japan and launch the product possibly this year, becoming the second Remicade biosimilar to be marketed in the country after Celltrion's Remsima.
You may also be interested in...
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
South Korean biotech firm Aprogen is emerging as another notable player in the increasingly crowded biosimilar space and the company has just reached its third worldwide biosimilar deal since 2014, again with Japan’s Nichi-Iko and this time for its rituximab product.
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.